There are currently 35 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are .
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/08/2025
Locations: Neumora Investigator site, Huntsville, Alabama +165 locations
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Encino, California +70 locations
Conditions: Major Depressive Disorder
Register for Updates
A Randomized Neuroimaging Trial of Psilocybin in Depression
NCT06072898
Recruiting
The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin: 1. Changes connectivity within brain networks associated with mood and depression 2. Changes blood flow in brain regions associated with mood and depression Participants will be attend two treatment sessi... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/08/2025
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Depressive Disorder, Major Depressive Disorder
Register for Updates
Personalized Indications for CBT and Antidepressants in Treating Depression
NCT02752542
Recruiting
Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsatisfactory response. On average, the combination of pharmacological and psychological treatment achieves better results than either treatment alone. However, the apparently superio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Nova Scotia Health Authority, Halifax, Nova Scotia
Conditions: Major Depressive Disorder, Persistent Depressive Disorder
Register for Updates
Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
NCT03601026
Recruiting
Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is poor and available treatments have limited efficacy. Most risk factors for SMI are either unchangeable (e.g., genetics) or difficult to alter (e.g., low socio-economic status). In contrast, cannabis use is one specific risk factor that could be avoided. Certain individuals are more vulnerable to the harmful effects of ca... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
05/13/2025
Locations: Nova Scotia Health Authority, Halifax, Nova Scotia
Conditions: Mental Illness, Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Cannabis Use, Psychosis
Register for Updates
Physical Activity Program for TRD
NCT06404320
Recruiting
This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario
Conditions: Treatment-resistant Depression, Major Depressive Disorder
Register for Updates
Temporal Interference and Depression
NCT05295888
Recruiting
Major Depressive Disorder (MDD) has a high prevalence, is the leading cause of disability, and currently available interventions are associated with side effects and high treatment resistance. There is an urgent need for the development of novel interventions for MDD with alternate mechanisms of action. Temporal Interference (TI) stimulation is a newly emerging form of transcranial alternating current stimulation (tACS) that involves the application of two high-frequency currents at slightly dif... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2025
Locations: Interventional Psychiatry Program, St. Michael's Hospital - Unity Health Toronto, Toronto, Ontario
Conditions: Major Depressive Disorder
Register for Updates
Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults
NCT03665831
Recruiting
In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate Alzheimer's disease (AD) or mild cognitive impairment (MCI) and comorbid Major Depressive Disorder (MDD) who have been unable to tolerate or failed to respond to antidepressant medications. The coil was designed to stimulate deeper regions of the left dorsolateral prefrontal cortex (DL... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/17/2025
Locations: Rotman Research Institute at Baycrest, Toronto, Ontario
Conditions: Major Depressive Disorder, Alzheimer Disease, Mild Cognitive Impairment
Register for Updates
I-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: a Randomized, Midazolam-Controlled Clinical Trial
NCT06480500
Recruiting
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years). Most people with depression experience thoughts of suicide and many will also plan and/or attempt suicide at some time in their life. There is an urgent need for new scalable treatments that can effectively reduce suicidality in people with depression. Cognitive behavioural therapy (CBT) reduces suicidal thoughts and behaviours, and can be de... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/26/2025
Locations: Toronto General Hospital, Toronto, Ontario +1 locations
Conditions: Major Depressive Disorder, Suicide, Treatment Resistant Depression
Register for Updates
Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
NCT04935619
Recruiting
The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Cannabis Use, Major Depressive Disorder, Cognitive Impairment
Register for Updates
Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation
NCT06763081
Recruiting
The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and adolescents with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
01/01/2025
Locations: Shared Health Facilities, Winnipeg, Manitoba +1 locations
Conditions: Behavioral Activation, Major Depressive Disorder, Anxiety Disorders, Antidepressant Drug Adverse Reaction, Obsessive Compulsive Disorder (OCD), Major Depression
Register for Updates
Patient-oriented Randomized Pragmatic Feasibility Trial with RTMS in Depression and Anxiety
NCT05028738
Recruiting
This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression (TRD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Non-Invasive Neurostimulation Therapies (NINET) Laboratory, UBC Department of Psychiatry, Vancouver, British Columbia
Conditions: Major Depressive Episode, Major Depressive Disorder
Register for Updates